[go: up one dir, main page]

CA2320626A1 - Vecteurs de vaccins mis au point par genie genetique - Google Patents

Vecteurs de vaccins mis au point par genie genetique Download PDF

Info

Publication number
CA2320626A1
CA2320626A1 CA002320626A CA2320626A CA2320626A1 CA 2320626 A1 CA2320626 A1 CA 2320626A1 CA 002320626 A CA002320626 A CA 002320626A CA 2320626 A CA2320626 A CA 2320626A CA 2320626 A1 CA2320626 A1 CA 2320626A1
Authority
CA
Canada
Prior art keywords
cells
genetic vaccine
vector
vectors
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002320626A
Other languages
English (en)
Inventor
Juha Punnonen
Willem P.C. Stemmer
Robert Gerald Whalen
Russell Howard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2320626A1 publication Critical patent/CA2320626A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des techniques permettant d'obtenir des vaccins génétiques à l'aide d'un réarrangement d'ADN. On peut, grâce à ces techniques, obtenir des vecteurs qui présentent une efficacité accrue, pouvant être utilisés comme vaccins génétiques. Ces techniques permettent également d'obtenir des vecteurs présentant, par exemple, une expression antigénique améliorée, une pénétration cellulaire accrue, une stabilité cellulaire augmentée, une aptitude à personnaliser une réponse immunitaire, etc.
CA002320626A 1998-02-11 1999-02-10 Vecteurs de vaccins mis au point par genie genetique Abandoned CA2320626A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2176998A 1998-02-11 1998-02-11
US7429498P 1998-02-11 1998-02-11
US09/021,769 1998-02-11
US60/074,294 1998-02-11
PCT/US1999/003022 WO1999041369A2 (fr) 1998-02-11 1999-02-10 Vecteurs de vaccins mis au point par genie genetique

Publications (1)

Publication Number Publication Date
CA2320626A1 true CA2320626A1 (fr) 1999-08-19

Family

ID=26695070

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002320431A Abandoned CA2320431A1 (fr) 1998-02-11 1999-02-10 Ciblage de vecteurs de vaccins genetiques
CA002320960A Abandoned CA2320960A1 (fr) 1998-02-11 1999-02-10 Optimisation des proprietes immunomodulatrices des vaccins genetiques
CA002320626A Abandoned CA2320626A1 (fr) 1998-02-11 1999-02-10 Vecteurs de vaccins mis au point par genie genetique

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA002320431A Abandoned CA2320431A1 (fr) 1998-02-11 1999-02-10 Ciblage de vecteurs de vaccins genetiques
CA002320960A Abandoned CA2320960A1 (fr) 1998-02-11 1999-02-10 Optimisation des proprietes immunomodulatrices des vaccins genetiques

Country Status (6)

Country Link
EP (3) EP1053343A2 (fr)
JP (3) JP2002503461A (fr)
AU (3) AU2674199A (fr)
CA (3) CA2320431A1 (fr)
MX (3) MXPA00007889A (fr)
WO (3) WO1999041368A2 (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
AU1449499A (en) 1997-10-31 1999-05-24 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6337186B1 (en) 1998-06-17 2002-01-08 Maxygen, Inc. Method for producing polynucleotides with desired properties
WO2000009682A1 (fr) 1998-08-12 2000-02-24 Maxygen, Inc. Rearrangement d'adn de genes de monoxygenase en vue de la production de produits chimiques industriels
WO2000020573A2 (fr) 1998-10-07 2000-04-13 Maxygen, Inc. Rearrangement d'adn pour produire des acides nucleiques de detoxication contre les mycotoxines
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP1129184A1 (fr) 1998-11-10 2001-09-05 Maxygen, Inc. Adp-glucose pyrophosphorylase modifiee pour l'amelioration et l'optimisation de phenotypes vegetaux
ATE439437T1 (de) 1999-01-05 2009-08-15 Univ Boston Verbessertes klonierungsverfahren
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
WO2000042560A2 (fr) 1999-01-19 2000-07-20 Maxygen, Inc. Methodes de fabrication de chaines de caracteres, de polynucleotides et de polypeptides
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
MXPA00009723A (es) * 1999-02-04 2003-09-22 Diversa Corp Generacion no estocastica de vacunas y enzimas geneticas.
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
CN1377406A (zh) 1999-07-22 2002-10-30 宝洁公司 具有空间保护的切割位点的蛋白酶缀合物
JP2003505070A (ja) 1999-07-22 2003-02-12 ザ、プロクター、エンド、ギャンブル、カンパニー 定められたエピトープ領域においてアミノ酸置換を有するサブチリシンプロテアーゼ変異体
CA2379712A1 (fr) 1999-07-22 2001-02-01 The Procter & Gamble Company Variants de protease subtilisine possedant des suppressions et des substitutions d'acides amines dans certaines regions de sites antigeniques
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
IL150291A0 (en) 2000-01-11 2002-12-01 Maxygen Inc Integrated systems and methods for diversity generation and screening
WO2001059071A2 (fr) 2000-02-09 2001-08-16 Genvec, Inc. Methodes de preparation et d'utilisation d'une bibliotheque de vecteurs viraux
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
AU5995701A (en) * 2000-05-26 2001-12-03 Univ Australian Synthetic peptides and uses therefore
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
AU2001268716A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel chimeric promoters
AU2001273009A1 (en) * 2000-06-26 2002-01-08 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
DE10060959A1 (de) * 2000-12-06 2002-06-20 Aventis Res & Tech Gmbh & Co Verfahren zur Isolierung und Identifizierung von Effektoren
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
CA2436214C (fr) * 2001-02-02 2012-12-04 Large Scale Biology Corporation Procede destine a ameliorer la complementarite d'un heteroduplex
WO2002094992A2 (fr) 2001-05-18 2002-11-28 Rigel Pharmaceuticals, Incorporated Evolution dirigee de proteine dans des cellules de mammifere
AU2002326437A1 (en) * 2001-07-19 2003-03-03 Icogen Corporation Methods for the identification of peptidyl compounds interacting with extracellular target molecules
WO2003045316A2 (fr) * 2001-11-21 2003-06-05 The Board Of Trustees Of The Leland Stanford Junior University Therapie par polynucleotide
CN1909922B (zh) 2002-02-26 2013-08-21 阿尔特拉瓦克斯股份有限公司 新的黄病毒抗原
AU2003216507A1 (en) 2002-03-01 2003-09-16 Maxygen, Inc. Methods, systems, and software for identifying functional bio-molecules
AU2003213846A1 (en) 2002-03-09 2003-09-29 Maxygen, Inc. Optimization of crossover points for directed evolution
EA010903B1 (ru) 2002-04-19 2008-12-30 Дайверса Корпорейшн Фосфолипазы, нуклеиновые кислоты, кодирующие их, и способы их получения и применения
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
DK1504098T4 (da) 2002-05-17 2011-05-23 Alligator Bioscience Ab Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
MXPA05001287A (es) 2002-08-06 2005-08-03 Verdia Llc Variantes de amino oxidasa ap1.
JP2006514549A (ja) 2002-12-16 2006-05-11 アメリカ合衆国 Ｉｌ−１５を発現する組換えワクチンウイルスおよびその使用方法
CA2920416A1 (fr) 2003-03-06 2004-10-28 Basf Enzymes Llc Amylases, acides nucleiques codant ces amylases et methodes de production et d'utilisation des amylases
MX295545B (es) 2003-03-07 2012-02-03 Diversa Corp Hidrolasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas.
DK1613733T3 (en) 2003-04-04 2015-08-31 Basf Enzymes Llc PEKTATLYASER, nucleic acids encoding them, and methods for making and using the
JP2007500514A (ja) 2003-04-29 2007-01-18 パイオニア ハイ−ブレッド インターナショナル， インコーポレイテッド 新規なグリホセートｎ−アセチルトランスフェラーゼ（ｇａｔ）遺伝子
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
BRPI0412279A (pt) 2003-07-02 2006-09-19 Diversa Corp glucanases, ácidos nucléicos codificando as mesmas e métodos para preparar e aplicar os mesmos
CA2535526C (fr) 2003-08-11 2015-09-29 Diversa Corporation Laccases, acides nucleiques codant pour ces enzymes et procedes permettant de les produire et de les utiliser
CA2735315A1 (fr) 2004-06-09 2005-12-29 Pioneer Hi-Bred International, Inc. Peptides de transit vers des plastes
EP2468853B1 (fr) 2004-06-16 2015-04-01 DSM IP Assets B.V. Procédé de décoloration enzymatique de la phéophytine
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CA2614769A1 (fr) 2005-03-10 2006-09-21 Verenium Corporation Lyases, acides nucleiques codant pour celles-ci et methodes de fabrication et d'utilisation
CN102943085A (zh) 2005-03-15 2013-02-27 维莱尼姆公司 纤维素酶、编码它们的核酸及其制备和应用的方法
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
EP2216403A3 (fr) 2006-02-02 2010-11-24 Verenium Corporation Estérases et acides nucléiques associés et procédés
NZ595497A (en) 2006-02-10 2013-09-27 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
EP2548954A1 (fr) 2006-02-14 2013-01-23 Verenium Corporation Xylanases, acides nucléiques les codant et leurs procédés de fabrication et dýutilisation
AU2007223913B2 (en) 2006-03-07 2013-06-13 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
EP1999256B1 (fr) 2006-03-07 2012-03-07 Verenium Corporation Aldolases, acides nucleiques les codant et procedes de fabrication et d'utilisation de celles-ci
MX369001B (es) 2006-08-04 2019-10-24 Basf Enzymes Llc Glucanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas.
PL2057274T3 (pl) 2006-09-21 2014-05-30 Dsm Ip Assets Bv Fosfolipazy, kodujące je kwasy nukleinowe i sposoby ich wytwarzania i stosowania
EP2617823B1 (fr) 2006-09-21 2015-07-01 BASF Enzymes LLC Phytases, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
ES2575912T3 (es) 2006-12-21 2016-07-04 Basf Enzymes Llc Amilasas y glucoamilasas, ácidos nucleicos que las codifican y métodos para formarlas y utilizarlas
WO2008095033A2 (fr) 2007-01-30 2008-08-07 Verenium Corporation Enzymes pour le traitement de matières lignocellulosiques, des acides nucléiques les codant et procédés pour leur fabrication et leur utilisation
NZ584967A (en) 2007-10-03 2012-08-31 Verenium Corp Xylanases, nucleic acids encoding them and methods for making and using them
RU2506275C2 (ru) 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
PL2238242T3 (pl) 2008-01-03 2015-06-30 Basf Enzymes Llc Transferazy i oksydoreduktazy, kwasy nukleinowe kodujące je oraz sposoby ich wytwarzania i zastosowania
US8541220B2 (en) 2008-01-03 2013-09-24 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
WO2009143397A2 (fr) 2008-05-23 2009-11-26 E. I. Du Pont De Nemours And Company Nouveaux gènes dgat permettant d'obtenir une production accrue de lipides de stockage de semences et des profils modifiés d'acides gras dans des plantes à graines oléagineuses
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
CN105274125A (zh) 2008-09-26 2016-01-27 托卡根公司 基因治疗载体和胞嘧啶脱氨酶
BRPI1011160A8 (pt) 2009-05-21 2018-01-02 Verenium Corp Fitases, preparação de proteína que as compreende, e seus usos
US8592649B2 (en) 2009-08-20 2013-11-26 Pioneer Hi Bred International Inc Functional expression of shuffled yeast nitrate transporter (YNT1) in maize to improve nitrate uptake under low nitrate environment
UA111708C2 (uk) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. Спосіб рафінування олії
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
MX2012007681A (es) 2009-12-31 2013-01-29 Pioneer Hi Bred Int Ingenieria de resistencia de plantas a enfermedades causadas por patogenos.
CA2805937A1 (fr) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Promoteurs chimeres et leurs methodes d'utilisation
CA2872096A1 (fr) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions et procedes comprenant des sequences ayant une activite de meganuclease
US20140287419A1 (en) 2013-03-14 2014-09-25 Arzeda Corp. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
EP2970935A1 (fr) 2013-03-14 2016-01-20 Pioneer Hi-Bred International, Inc. Compositions ayant une activité de décarboxylase de dicamba et leurs procédés d'utilisation
WO2014150914A2 (fr) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Polypeptides phi-4 et leurs procédés d'utilisation
EP3032942B1 (fr) 2013-08-16 2020-03-11 Pioneer Hi-Bred International, Inc. Protéines insecticides et leurs procédés d'utilisation
CA2923726C (fr) 2013-09-13 2024-01-30 Pioneer Hi-Bred International, Inc. Proteines insecticides et leurs procedes d'utilisation
CN106536545A (zh) 2014-02-07 2017-03-22 先锋国际良种公司 杀昆虫蛋白及其使用方法
BR112016018103B1 (pt) 2014-02-07 2024-01-16 E.I. Du Pont De Nemours And Company Polipeptídeo e seu uso, polinucleotídeo, composição, proteína de fusão, método para controlar uma população, método para inibir o crescimento, método para controlar a infestação, método para obtenção de uma planta ou célula vegetal, construto
SG11201701669PA (en) * 2014-09-11 2017-04-27 Vlp Therapeutics Llc Flavivirus virus like particle
US10435706B2 (en) 2014-10-16 2019-10-08 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
US10231460B2 (en) 2015-01-15 2019-03-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
MX376048B (es) 2015-03-11 2025-03-07 Corteva Agriscience Llc Combinaciones insecticidas de pip-72 y métodos de uso.
WO2016186986A1 (fr) 2015-05-19 2016-11-24 Pioneer Hi Bred International Inc Protéines insecticides et leurs procédés d'utilisation
US11198709B2 (en) 2015-08-06 2021-12-14 E. I. Du Pont De Nemours And Company Plant derived insecticidal proteins and methods for their use
US20180325119A1 (en) 2015-12-18 2018-11-15 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
US11008585B2 (en) 2016-05-04 2021-05-18 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
ES2821876T3 (es) * 2016-06-20 2021-04-28 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado
PH12018502706B1 (en) 2016-07-01 2024-05-24 Pioneer Hi Bred Int Insecticidal proteins from plants and methods for their use
CN109863167B (zh) 2016-11-01 2022-12-23 先锋国际良种公司 杀昆虫蛋白及其使用方法
US11174295B2 (en) 2016-12-14 2021-11-16 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3046226A1 (fr) 2016-12-22 2018-06-28 Pioneer Hi-Bred International, Inc. Proteines insecticides et leurs procedes d'utilisation
WO2018148001A1 (fr) 2017-02-08 2018-08-16 Pioneer Hi-Bred International Inc Associations insecticides de protéines insecticides d'origine végétale et leurs procédés d'utilisation
BR112019023628A2 (pt) 2017-05-11 2020-06-02 Pioneer Hi-Bred International, Inc. Polipeptídeo inseticida recombinante, proteína inseticida quimérica, proteína de fusão, composição agrícola, polinucleotídeo recombinante, construto de dna, planta transgênica, método para inibir o crescimento ou exterminar uma praga de inseto ou população de praga, método para controlar os danos por praga de inseto, método para controlar infestação de praga e método para melhorar o rendimento de uma cultura
MX2020009435A (es) 2018-03-14 2020-11-11 Pioneer Hi Bred Int Proteinas con actividad insecticida de plantas y metodos para sus usos.
EP4659582A2 (fr) 2018-03-14 2025-12-10 Pioneer Hi-Bred International, Inc. Protéines insecticides issues de plantes et leurs procédés d'utilisation
CN113874392B (zh) 2019-03-28 2025-10-21 丹尼斯科美国公司 工程化抗体
CN115151643A (zh) 2020-01-10 2022-10-04 加利福尼亚大学董事会 用于产生橄榄醇酸和橄榄醇酸类似物的生物合成平台
WO2022015619A2 (fr) 2020-07-14 2022-01-20 Pioneer Hi-Bred International, Inc. Protéines insecticides et leurs procédés d'utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
IL96475A0 (en) * 1989-11-29 1991-08-16 Innovative Tech Center Chimeric proteins
CA2160878A1 (fr) * 1993-04-19 1994-10-27 Sandra Gertrude Mcelligott Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression genique
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
WO1994026787A1 (fr) * 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Procede pour generer des bibliotheques d'anticorps de phages specifiques de types cellulaires
SE9304060D0 (sv) * 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
EP0789774A2 (fr) * 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Reponse immunitaire amelioree par l'introduction par recombinaison du gene de la cytokine et/ou du gene de la proteine co-stimulatrice b7 dans un systeme d'expression virale
WO1996013250A1 (fr) * 1994-10-27 1996-05-09 Amgem Inc. Compositions pour une assimilabilite accrue d'agents therapeutiques administres par voie orale
CA2211993A1 (fr) * 1995-01-31 1996-08-08 The Rockefeller University Identification de la proteine membranaire, integrale dec (cellules dendritiques et epitheliales, 205 kda), un recepteur a domaines lectiniques de type c, des acides nucleiques codant dec, ainsi que ses applications
CA2230195A1 (fr) * 1995-08-21 1997-02-27 Duke University Procede pour accroitre la densite d'un antigene sur une cellule presentant un antigene
NZ319891A (en) * 1995-09-28 1999-01-28 Univ Pittsburgh Stimulation of cytotoxic t lymphocyte response to tumour or virus by targeted particulate polynucleotide genetic immunisation
US6489145B1 (en) * 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling
WO1997032987A1 (fr) * 1996-03-08 1997-09-12 University Of Toronto Procede et compositions nucleiques immunogenes codant pour des antigenes, et molecules co-stimulant l'immunisation
US6096548A (en) * 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus

Also Published As

Publication number Publication date
WO1999041369A2 (fr) 1999-08-19
WO1999041368A3 (fr) 1999-12-16
MXPA00007893A (es) 2002-10-23
WO1999041402A3 (fr) 1999-11-11
MXPA00007891A (es) 2002-09-18
AU2674299A (en) 1999-08-30
JP2002507392A (ja) 2002-03-12
EP1053312A2 (fr) 2000-11-22
CA2320431A1 (fr) 1999-08-19
EP1053343A2 (fr) 2000-11-22
WO1999041369A3 (fr) 1999-09-23
AU2674199A (en) 1999-08-30
WO1999041402A2 (fr) 1999-08-19
JP2002503461A (ja) 2002-02-05
JP2002503478A (ja) 2002-02-05
EP1056842A2 (fr) 2000-12-06
AU3291099A (en) 1999-08-30
CA2320960A1 (fr) 1999-08-19
MXPA00007889A (es) 2002-09-18
WO1999041368A2 (fr) 1999-08-19

Similar Documents

Publication Publication Date Title
CA2320626A1 (fr) Vecteurs de vaccins mis au point par genie genetique
US20010006950A1 (en) Genetic vaccine vector engineering
CA2325351C (fr) Elaboration non stochastique de vaccins genetiques et d'enzymes
US20080019988A1 (en) Targeting of genetic vaccine vectors
US6706477B2 (en) Methods for producing polynucleotide libraries in vaccinia virus
US6479258B1 (en) Non-stochastic generation of genetic vaccines
CA2350207C (fr) Lymphocytes t specifiques d'antigenes cible, vaccins prepares a partir desdits lymphocytes, et methodes associees
WO2002092780A2 (fr) Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules
CA2268265A1 (fr) Procedes permettant l'optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences
US7390619B1 (en) Optimization of immunomodulatory properties of genetic vaccines
CA2446260C (fr) Nouveaux vecteurs d'expression et utilisations correspondantes
AU2757902A (en) Genetic vaccine vector engineering
US20070258993A1 (en) Dna-Carrier Conjugate
CA2492661C (fr) Elaboration non stochastique de vaccins genetiques et d'enzymes
AU2767702A (en) Targeting of genetic vaccine vectors
EP2049154A1 (fr) Plasmides ayant une action immunologique
CN116761811A (zh) 用于诱导免疫应答的缀合多肽和疫苗
EP1518927A2 (fr) Optimisation des propriétés immunomodulatrices de vaccins génétiques
Pascolo Plasmid DNA and messenger RNA for therapy
AU2761302A (en) Optimization of immunomodulatory properties of genetic vaccines
AU2002318140A1 (en) Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Legal Events

Date Code Title Description
FZDE Discontinued